Co
Corvus Pharma
Burlingame CAFounded 201430 employees
Private CapbiotechAcquiredOncology
Platform: A2aR Adenosine
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Voxasotorasib | COR-4636 | Phase 3 | 3 | CD38 | Ewing SarcomaAS | ||
| COR-7645 | COR-7645 | NDA/BLA | 2 | IL-13 | Crohn'sBCC | ||
| Adagrazasiran | COR-2207 | Phase 3 | 1 | FLT3 | SchizophreniaParkinson's | ||
| Sovafotisoran | COR-9546 | Preclinical | 1 | KRASG12D | PBCBCC |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (8)